Donglin Liu

Leading discovery and preclinical development of antibody therapeutics, bispecific antibodies, T-cell engager programs, and next-generation ADCs for oncology applications. Designing and executing cell-based bioassays, including flow cytometry-based functional characterization, cytotoxicity, apoptosis, proliferation, and mechanism-of-action studies. Driving target validation, antibody engineering, and functional characterization of novel biologic therapeutic platforms, including MG-Ig bispecific technologies. Developing analytical and bioassay platforms for biologics characterization, including Biacore (SPR), ELISA, flow cytometry, qPCR, HPLC, and mass spectrometry. Managing scientific collaborations with academic institutions, CROs, and external research partners. Leading intellectual property generation for innovative oncology biologics platforms.

➤ Played a vital role in the targeted delivery and cytotoxic mechanism of SN38-based antibody-drug conjugates. ➤ Contributed to development of Trop-2-targeted therapeutics that later achieved FDA breakthrough therapy. ➤ Exploration and innovative research in CAR-NK and CAR-T therapies, utilizing Trop2-targeted antibodies to enhance the efficacy of cell-based cancer immunotherapy. ➤ Led as a principal investigator the creation of novel immunoRNases for targeted therapy of solid cancer and lymphoma, supported by the prestigious NIH SBIR grant (1R43CA180343-01). ➤ Identified MUC5AC as a pivotal biomarker and drug target for pancreatic cancer, resulting in Patent US 9,005,613 B2. ➤ Strategically led the humanization of mouse anti-hPD-1 antibody with a focus on enhancing the antitumor potency of bispecific t-cell engagers. ➤ Pioneered innovative research into the targeted delivery of interferon-λ1 using antibodies to enhance both anti-tumor and anti-viral activities. ➤ Led a team of Scientists and Research Associates, ensuring efficient progress across multiple research endeavors. ➤ Took charge of experimental design, execution, troubleshooting, data analysis, and interpretation. ➤ Drafted technical reports and regularly delivered project updates to senior management, facilitating decision-making. ➤ Authored influential publications, spearheaded grant applications, and represented the organization at both internal and external scientific conferences, enhancing the company's scientific reputation. ➤ Identified disease-specific biomarkers and mapping epitopes for diagnostic and therapeutic antibodies. ➤ Maintained a strong focus on antibody development, including humanization, production, and drug conjugation. ➤ Used routine lab techniques, such as real-time qPCR, SDS-PAGE, HPLC, Mass spectrometry, flow cytometry, ELISA, and Western blot etc. ➤ Showcased expertise in DNA cloning, RNAi, Dot blot, pharmacokinetic (PK) analysis, and other molecular biology techniques.

➤ Research Scientist – Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ – 07/2007 to 03/2010 ➤ Research & Teaching Specialist – Department of Biochemistry and Molecular Biology, New Jersey Medical School, Rutgers University, Newark, NJ – 10/2003 to 05/2005